Compounders Research Compare

Shattuck Labs, Inc.(STTK)

Biotechnology · Austin, TX

$5.86-0.64 (-9.85%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Shattuck Labs, Inc.

Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.

Austin, TX

40 employees

www.shattucklabs.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Taylor H. Schreiber

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T22:43:21.465Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:43:21.465Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 529,582,205
Total debt · period ending 2026-06-30: 2,674,000
Cash · period ending 2026-06-30: 63,299,000
TTM free cash flow · period ending 2026-06-30: -41,240,000

FMP input reference: 35a271d61501d442ff1d5238fcf80e89d6bdfa5e87b371fe53e06a7cba571f48

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

STTK EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

STTK Competitors' EV/FCF Ratio

Shattuck Labs, Inc.

Current

Market Cap

$529.58M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Nuvectis Pharma, Inc.

Market Cap

$531.52M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Delcath Systems, Inc.

Market Cap

$531.98M

EV/FCF Ratio

27.81x

TTM Avg

31.80x

3Y Avg

42.09x

5Y Avg

42.09x

Monopar Therapeutics Inc.

Market Cap

$533.04M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Immix Biopharma, Inc.

Market Cap

$524.43M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ProKidney Corp.

Market Cap

$538.01M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Altimmune, Inc.

Market Cap

$519.25M

EV/FCF Ratio

N/A

TTM Avg

0.12x

3Y Avg

0.12x

5Y Avg

0.12x

Aclaris Therapeutics, Inc.

Market Cap

$516.76M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Phathom Pharmaceuticals, Inc.

Market Cap

$548.51M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

908 Devices Inc.

Market Cap

$505.87M

EV/FCF Ratio

927.69x

TTM Avg

716.21x

3Y Avg

716.21x

5Y Avg

716.21x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Shattuck Labs, Inc. (STTK)	$529.58M	N/A	N/A	N/A	N/A
Nuvectis Pharma, Inc. (NVCT)vs ›	$531.52M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$531.98M	27.81x	31.80x	42.09x	42.09x
Monopar Therapeutics Inc. (MNPR)vs ›	$533.04M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$524.43M	N/A	N/A	N/A	N/A
ProKidney Corp. (PROK)vs ›	$538.01M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$519.25M	N/A	0.12x	0.12x	0.12x
Aclaris Therapeutics, Inc. (ACRS)vs ›	$516.76M	N/A	N/A	N/A	N/A
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$548.51M	N/A	N/A	N/A	N/A
908 Devices Inc. (MASS)vs ›	$505.87M	927.69x	716.21x	716.21x	716.21x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics